The results showed that RITA could promote sorafenib sensitivity in RCC cells and diminish the distinct difference in the IC50 of sorafenib and the cell death proportion after sorafenib treatment between ANGPTL3-knockdown and control RCC cells (Fig. 6f, g). This evidence concerns the gene ANGPTL3 and renal cell carcinoma.